Allena Pharmaceuticals, Inc. Common Stock (Net)

Common Stock (Net) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Common Stock (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Common Stock (Net) for the quarter ending March 31, 2022 was $90 Thousand (a 8.43% increase compared to previous quarter)
  • Year-over-year quarterly Common Stock (Net) increased by 52.54%
  • Annual Common Stock (Net) for 2021 was $83 Thousand (a 62.75% increase from previous year)
  • Annual Common Stock (Net) for 2020 was $51 Thousand (a 104.0% increase from previous year)
  • Annual Common Stock (Net) for 2019 was $25 Thousand (a 19.05% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Common Stock (Net) of Allena Pharmaceuticals, Inc.

Most recent Common Stock (Net)of ALNA including historical data for past 10 years.

Interactive Chart of Common Stock (Net) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Common Stock (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.09
2021 $0.08 $0.08 $0.06 $0.06 $0.08
2020 $0.05 $0.04 $0.03 $0.03 $0.05
2019 $0.03 $0.02 $0.02 $0.02 $0.03
2018 $0.02 $0.02 $0.02 $0.02 $0.02
2017 $0.02 $0.0 $0.0 $0.0 $0.02
2016 $0.0 $0.0
2015 $0.0 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.